Every year, a mid-size pharmaceutical organization generates thousands of research documents, clinical trial reports, and complex regulatory submissions. Yet, the vast majority of these documents are filed away and never systematically accessed again.

This isn't just an operational inefficiency; it is one of the most expensive knowledge problems in any industry today. When highly paid scientists and researchers cannot find past data, they are forced to recreate it. Solving this issue requires more than just a better enterprise search tool – it requires an infrastructure that turns static files into active, accessible intelligence.

The Knowledge Challenge in Pharma

Pharmaceutical companies accumulate vast amounts of unstructured knowledge at a staggering pace. This includes decades of preclinical research, clinical trial data, regulatory submissions, competitor intelligence, and endless volumes of scientific literature. The fundamental challenge in life sciences is not generating new knowledge – it is accessing and activating that existing knowledge across different teams and timelines. In fact, this unstructured business intelligence is estimated to make up as much as 90% of the data generated by organizations.

Right now, 97% of organizations face context gaps across definitions, quality, and trust that block AI from scaling. When valuable research data remains trapped in legacy formats, scientists simply cannot use it to inform new drug discovery. To truly capitalize on AI, the industry must first solve this massive gap.

Three Ways AI Is Changing Knowledge Work in Life Sciences

When pharmaceutical companies successfully implement structured AI, it fundamentally changes how they operate. Here are three ways AI is transforming knowledge work in life sciences:

1. Research synthesis at scale 

Instead of researchers spending weeks manually reviewing literature, AI agents can autonomously surface relevant prior work across both internal and external repositories. For internal intelligence, platforms like Iris.ai’s Axion unify scattered organizational data, allowing teams to easily search all prior work and drastically reduce duplicated R&D effort. Meanwhile, tools like Iris.ai’s RSpace enable researchers to quickly filter through massive volumes of up-to-date, cross-disciplinary scientific literature. As demonstrated in a recent public sector case study, researchers used RSpace to rapidly narrow down relevant external papers for time-sensitive risk assessments on niche topics like avian flu, streamlining data collection and accelerating project delivery.

2. Regulatory knowledge management 

AI provides structured, instant access to historical submission data and complex compliance requirements. Agents can cross-reference new drug applications against decades of past regulatory feedback, ensuring consistency and proactively flagging potential compliance risks before submission.

3. Competitive intelligence 

AI systems transform competitive analysis by automatically extracting relevant, usable data points from massive volumes of provided patents, clinical trial registries, and scientific literature. This allows R&D teams to rapidly synthesize complex technical details to monitor competitor pipelines and emerging therapeutic areas in real-time. As demonstrated by ArcelorMittal’s global R&D team, automatically extracting product intelligence and specific data points from complex research patents cut their patent analysis workload by over 90% and accelerated data extraction by 60x.

What Makes This Work: The Infrastructure Layer

AI in pharma consistently fails when it operates on fragmented, ungoverned knowledge. Despite massive investments across industries, only 17% report that AI is operationalized and driving business value.

The organizations actually seeing results have recognized that successful AI requires a unified infrastructure layer. Winning programs start by investing in a data foundation that physically connects isolated internal repositories, structures massive volumes of unstructured dark data, and strictly enforces AI governance over who can access sensitive trial results. Once that highly structured data foundation is set, the next step is activating it. As discussed in a recent HumBot podcast, the secret to navigating from data chaos to AI-ready intelligence is building an enterprise agentic RAG architecture right on top of that unified knowledge base.

When this infrastructure is in place, the results are profound. Currently, 34% of companies are starting to use AI to deeply transform their businesses, rather than just optimizing old processes.

By deploying Iris.ai as a connective layer that understands complex, domain-specific scientific context, pharma organizations can ensure their AI operates on a grounded, auditable, and highly structured knowledge foundation.

Conclusion

The pharmaceutical organizations that will lead the next decade are the ones treating their knowledge infrastructure as a strategic investment rather than a simple backend IT cost.

The scientific data and research you need to drive your next major breakthrough already exists within your systems; the only question is whether that data is actively working for you. By unifying your knowledge layer, you can turn decades of research into your greatest competitive advantage.

See How Iris.ai Powers Knowledge Work in Life Sciences → Explore Case Studies